Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2005

View Archived Issues

Schering AG plans additional phase III Crohn's disease trial for sargramostim

Phase IIa trials begin for melanoma vaccine CYT-004-MelQbG10

ABC2 and Genentech collaborate to study Avastin for GBM

Ranbaxy completes proof-of-concept for antimalarial RBx-11160

Orapred ODT filing accepted for review

Ark receives license to manufacture commercial supplies of gene-based medicine

Intercell aligns with CDC for development of Pneumococcus vaccine

New phase I study for Amplimexon plus docetaxel in cancer patients

Phase II study of Xanafide plus ara-C for secondary AML

Alinea announces Series A financing

Cardium Therapeutics and Aries Ventures to merge

Idera seeks to amend HYB-2055 phase II protocol

Viprovex studied as potential treatment for anthrax infection

Etomoxir reemerges as a potential antipsoriatic agent

Living Cell Technologies requests pre-IND meeting for NeurotrophinCell product

MedImmune and Avidia combine strengths to develop anticancer products

Repositioning study indicates utility of EVT-201 for insomnia

Approvable letter for Sparlon for ADHD

Levemir approved for use in children

New data on the immunomodulatory effects of FTY-720

SP-600125 evokes suppression of primary T-cell inhibition in vitro

Therapeutic benefits reported for transdermal lisuride in RLS

New data supports the use of pramipexole in restless legs syndrome

Low toxicity, beneficial activity seen with BLP25 liposome vaccine in lung cancer

Tesaglitazar improves lipids, glucose metabolism in insulin-resistant subjects

Recent patents cover new agents for inflammatory disorders

New therapeutics for cancer disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...